What Is D’OXYVA?


What Is D'OXYVA?

The D’OXYVA® device is a simple, commercially available medical device to deliver transdermal carbon dioxide (CO2). It consists of a patented and patent-pending ergonomic polymer shell that is propelled by a patented  steel pressurized cylinder filled with pharmaceutical-grade (99.5%) liquid, purified CO2. The mini steel cylinder is GMP-compliant and recyclable.

D’OXYVA was identified by the IRB in a human clinical trial as a nonsignificant risk (NSR) device.

The D’OXYVA device is manufactured in the United States and other countries. D’OXYVA is an ISO-compliant device, which means that Circularity Healthcare, LLC has received a certification that D’OXYVA fulfills all of the international requirements for medical device regulations, such as risk assessment and maintaining effective processes for safe design, manufacturing, and distribution. 

D’OXYVA (deoxyhemoglobin vasodilator) is the only fully non-invasive, non-irritating, non-opioid, and completely painless, transdermal (over-the-skin) microcirculatory solution.

With over five years of industry-leading clinical research results, D’OXYVA demonstrated that it does not break the skin’s barrier while it provides outsized quality of life and clinical outcomes quickly and affordably. 

In short, based on current leading neurology, immunology, microvascular, and cellular oxygenation science, D’OXYVA is leading the field by: 


Significantly lowering the risk of diabetes and cardiovascular complications 

Providing complete healing of difficult wounds together with major pain relief and improved quality of life


D’OXYVA‘s gentle vapor solution with purified medical CO2 readily dissolves in a molecular form in the skin, acting as a catalyst to improve skin perfusion pressure and optimize nerve functions and microcirculation. 

Non-electrical, handheld, painless

Fast & easy use virtually anywhere

Learn how to use D’OXYVA >>

Check the prices in our Shop Page >>

Who is involved in improving health care for patients?

COis the protagonist in D’OXYVA’s revolutionary approach to improving health care and patients’ quality of life. The medical device causes controlled ischemia-like stress in a local area of the body to promote central nervous system activity and circulate humoral agents that favor microcirculation, especially at the organ capillary beds. Adequate blood flow in the capillary bed is essential for tissue survival and optimal organ function. If blood passes too quickly or does not pass at all, the tissue cannot extract Oefficiently and will generate what is known as capillary dysfunction, which is related to chronic pain, poor wound healing, diabetic neuropathy, and Alzheimer’s disease, among other conditions.

Where does COvapor delivered through the skin take action in the body?

Transdermal delivery of COhas proven to improve local microcirculation (capillary beds) blood flow and tissue perfusion, but it also positively improves systemic blood pressure and TcpO(most likely due to the Bohr Effect). As mentioned before, therapeutic medical-grade COis used for vasodilatation in the medical field for several conditions and procedures.
Local COtherapy has shown great success in improving the health care of patients through the following:

  • Treatment for diabetic foot
  • Increased microcirculation blood flow and dissociated Oin healthy and diabetic individuals
  • Treatment for arterial stenosis obliterans
  • Chronic wound healing
  • Adipose tissue treatment

Systemically, COtherapy has shown great success in improving the following:

  • The health care of patients with high blood pressure
  • General vital organ function, such as that of the:

– Pancreas – Liver – Brain – Kidneys

We are currently finding clinical researchers who are interested in participating in clinical trials with our medical device. Our goal is to produce scientific evidence of D’OXYVA’s potential to improve health care. Please send us a message if you are interested to paticipate.